Compare RLMD & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | KOP |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.9M | 784.7M |
| IPO Year | 2012 | 2005 |
| Metric | RLMD | KOP |
|---|---|---|
| Price | $5.30 | $48.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $12.40 | ★ $52.50 |
| AVG Volume (30 Days) | ★ 2.4M | 155.0K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | ★ 45.28 | 11.38 |
| EPS | N/A | ★ 0.35 |
| Revenue | $13,070.00 | ★ $1,879,300,000.00 |
| Revenue This Year | N/A | $2.91 |
| Revenue Next Year | N/A | $1.86 |
| P/E Ratio | ★ N/A | $139.81 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.55 | $25.00 |
| 52 Week High | $8.00 | $50.00 |
| Indicator | RLMD | KOP |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 67.80 |
| Support Level | $4.06 | $26.47 |
| Resistance Level | $7.28 | N/A |
| Average True Range (ATR) | 0.40 | 1.64 |
| MACD | -0.11 | 0.17 |
| Stochastic Oscillator | 0.00 | 79.34 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.